Compare MC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | ACAD |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | 2014 | 2000 |
| Metric | MC | ACAD |
|---|---|---|
| Price | $54.55 | $18.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $67.50 | $30.53 |
| AVG Volume (30 Days) | 917.1K | ★ 2.3M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.75 | 0.20 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $14.07 | $18.71 |
| Revenue Next Year | $17.57 | $12.44 |
| P/E Ratio | ★ $73.77 | $98.53 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $51.06 | $18.39 |
| 52 Week High | $78.22 | $30.96 |
| Indicator | MC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 26.82 |
| Support Level | $51.06 | N/A |
| Resistance Level | $56.79 | $22.92 |
| Average True Range (ATR) | 1.77 | 0.57 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 20.70 | 36.57 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.